NextCell’s CSO nominated for ISCT European Regional Secretary
NextCell Pharma AB’s ("NextCell" or the "Company") CSO, Lindsay Davies, has been nominated for the position of European Regional Secretary for the International Society for Cell and Gene Therapy.
The International Society of Cell and Gene Therapy is the global leader in pre-clinical and translational cell and gene therapeutics. Dr Davies received notification from ISCT’s President Elect, Chair of the Nominations Committee and CEO, that the Board of Directors had approved the nomination.
In response to the nomination, Dr Davies said, “It is an honor to be nominated for this prestigious role with ISCT. I would be delighted to have the opportunity to give back to a society that has offered me so much during my career development”.
At the forefront of cell and gene therapy (CGT), ISCT provides a global platform influencing and spearheading policy development, regulations and cutting edge research through their committees, positional papers, and training programs. Dr Davies was asked what she would like to achieve during her term if elected to the role of European Regional Secretary. She responded that she would like to see open discussions between regulators, industrial partners, and healthcare providers to address the issues regarding financial and regulatory hurdles for European CGT developers. “As a global society ISCT has the potential to influence, improve and strengthen governance and policy with respect to manufacturing regulations, commercialization, and reimbursement strategies. I would welcome the opportunity to support a European movement to see CGTs being offered as standard line of care where needed, irrespective of country of residence”.
If elected, Dr Davies will represent NextCell and Sweden, in the European Executive Committee, a group of five elected individuals who have been selected as worldclass representatives for European CGT. Dr Davies brings a rare and valuable viewpoint, having worked in the CGT field for twenty years as a cell biologist in academia, in translational medicine developing CGT products for the clinic and in industry as a CSO for NextCell working towards commercializing their clinical drug candidate, ProTrans.
Voting for ISCT’s election is now open to ISCT members. Results of the election will be released after closure of the voting on March 10th.
For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com
Website:
NextCell Pharma AB: www.nextcellpharma.com
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser, info@fnca.se.
About NextCell Pharma AB
NextCell is a cell therapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stromal cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to market approval for type-1 diabetes via a phase III study. ProTrans is evaluated in two clinical COVID-19 studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5% of FamicordTX, a start-up company in CAR-T and oncology, and 100% of Cellaviva, Scandinavia's largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).